Skip to main content
. Author manuscript; available in PMC: 2011 May 3.
Published in final edited form as: Cancer Treat Res. 2009;151:139–161. doi: 10.1007/978-0-387-75115-3_10

Table 4. Trials comparing initial tamoxifen with aromatase inhibition.

Study Patient population Intervention Results Ref
ATAC
(N = 9,366)		 Postmenopausal A × 5 yr
vs
T × 5 yr
vs
A + T × 5 yr		 A>T for DFS
A+T = T		 [60, 61]
BIG I-98
(N = 8,028)		 Postmenopausal ER+ and/or PR+ T × 5 yr
vs
L × 5 yr
vs
T × 2 yr, L × 3 yr
vs
L × 2 yr, T × 3 yr		 L>T for DFS*
L>T for distant recurrence
*T compared to L upfront only		 [62, 63]
TEAM Postmenopausal T × 5 yr
vs
E × 5 yr
vs
T × 2 yr, E × 3 yr
vs
E × 2 yr, T × 3 yr		 NR, ongoing –

ATAC = Arimidex, Tamoxifen, Alone or in Combination; A = Arimidex; T = Tamoxifen; DFS = disease-free survival; BIG = Breast International Group; ER = estrogen receptor; PR = progesterone receptor; L = Letrozole; TEAM = Tamoxifen and Exemestane Adjuvant Multicenter; E = Exemestane; NR = not reported